63 results
10-Q
2021 Q3
CGTX
Cognition Therapeutics Inc
17 Nov 21
Quarterly report
5:15pm
of operations;
We may be subject to securities litigation, which is expensive and could divert our management’s attention;
We have incurred … and December 31, 2020, there was no litigation or contingency with at least a reasonable possibility of a material loss.
6. Debt
On March 8, 2018
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
litigation, starting at the end of the five-year NCE regulatory exclusivity period).
In addition to patent exclusivity, under the provisions … parties, and such licenses may not be available or may not be available on commercially reasonable terms.
Third-party claims or litigation alleging
10-K
2021 FY
CGTX
Cognition Therapeutics Inc
30 Mar 22
Annual report
7:40am
, and such licenses may not be available or may not be available on commercially reasonable terms.
third-party claims or litigation alleging infringement of patents … or judicial decisions in the patent litigation, starting at the end of the five-year NCE regulatory exclusivity period).
In addition to patent
DRS
CGTX
Cognition Therapeutics Inc
20 Oct 22
Draft registration statement
12:00am
or there are certain settlements or judicial decisions in the patent litigation, starting at the end of the five-year NCE regulatory exclusivity period … or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent
424B4
vvlfz
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
g8bmif1oml wofdyulz
19 Jul 21
IPO registration
7:02am
DRS
35rim
7 May 21
Draft registration statement
12:00am
DRS/A
byb9drsi9tkq
23 Jun 21
Draft registration statement (amended)
12:00am
8-K
EX-99.2
ionkb5nwobad yz99
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
dgwymav
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-99.1
c50p7 7p7qh
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
njnuoa2k8kwjk1ny0jin
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
S-3
ct9bm68ao
23 Dec 22
Shelf registration
4:16pm